Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018–2024
- Chris Edens; Benjamin Clopper; Jourdan DeVies; Alvaro Benitez; Erin McKeever; Dylan Johns
PMID: 38386615DOI: 10.15585/mmwr.mm7307a3
Access Resources
About
Data from NSSP and NVSN reveals a decrease in M. pneumoniae diagnoses and positive test results during the COVID-19 pandemic. Although there has been an increase post-September 2023, levels are still below those seen before the pandemic. The report emphasizes the importance of ongoing monitoring for M. pneumoniae infections and resistance. Providers are advised to include M. pneumoniae in the differential diagnosis for community-acquired pneumonia, especially in fall and winter. Despite concerns about antimicrobial resistance, macrolides remain the primary treatment for M. pneumoniae infections in the United States.Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.